Ligand Pharmaceuticals Incorporated
US ˙ NasdaqGM ˙ US53220K5048

SecurityLGND / Ligand Pharmaceuticals Incorporated
InstitutionCornerstone Capital, Inc.
Latest Disclosed Ownership7,856 shares
Latest Disclosed Value $ 1,568,517
Cornerstone Capital, Inc. reports 53.53% increase in ownership of LGND / Ligand Pharmaceuticals Incorporated

On May 12, 2026 - Cornerstone Capital, Inc. filed a 13F-HR form disclosing ownership of 7,856 shares of Ligand Pharmaceuticals Incorporated (US:LGND) valued at $1,568,450 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 5,117 shares of Ligand Pharmaceuticals Incorporated. This represents a change in shares of 53.53% during the quarter. The current value of the position is $1,841,446 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 7,856 2,739 53.53 1,569 62.15 0.1567
2026-02-12 2025-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 5,117 -70 -1.35 968 5.34 0.0954
2025-11-10 2025-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 5,187 -550 -9.59 919 40.80 0.0899
2025-08-12 2025-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 5,737 0 0.00 652 8.13 0.0682
2025-05-13 2025-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 5,737 -760 -11.70 603 -13.36 0.0649
2025-02-13 2024-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 6,497 0 0.00 696 7.08 0.0733
2024-10-30 2024-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 6,497 0 0.00 650 18.83 0.0607
2024-08-02 2024-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 6,497 0 0.00 547 15.40 0.0552
2024-05-01 2024-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 6,497 -460 -6.61 475 -4.44 0.0487
2024-02-02 2023-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 6,957 -547 -7.29 497 10.47 0.0544
2023-11-13 2023-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 7,504 -3,522 -31.94 450 -43.45 0.0542
2023-08-21 2023-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 11,026 -2,489 -18.42 795 -20.12 0.0920
2023-05-15 2023-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 13,515 -155 -1.13 994 8.87 0.1200
2023-02-13 2022-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 13,670 -1,775 -11.49 913 -31.35 0.1170
2022-10-27 2022-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 15,445 0 0.00 1,330 -3.48 0.1869
2022-08-15 2022-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 15,445 0 0.00 1,378 -20.67 0.1766
2022-05-13 2022-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 15,445 1,325 9.38 1,737 -20.36 0.1949
2022-02-11 2021-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 14,120 -643 -4.36 2,181 6.03 0.2324
2021-11-09 2021-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 14,763 0 0.00 2,057 6.20 0.2371
2021-08-13 2021-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 14,763 0 0.00 1,937 -13.95 0.2197
2021-05-17 2021-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 14,763 -9,812 -39.93 2,251 -7.90 0.2723
2021-02-12 2020-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 24,575 15,160 161.02 2,444 172.46 0.3144
2020-10-27 2020-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 9,415 101 1.08 897 -13.92 0.1292
2020-08-14 2020-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 9,314 -916 -8.95 1,042 40.05 0.1776
2020-05-15 2020-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 10,230 -649 -5.97 744 -34.45 0.1547
2020-02-10 2019-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 10,879 -61 -0.56 1,135 4.22 0.1601
2019-11-13 2019-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 10,940 -122 -1.10 1,089 -13.78 0.1694
2019-08-14 2019-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 11,062 -8,241 -42.69 1,263 -47.96 0.1981
2019-05-15 2019-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 19,303 -44,570 -69.78 2,427 -72.00 0.4013
2019-02-11 2018-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 63,873 677 1.07 8,668 -50.03 1.5452
2018-11-13 2018-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 63,196 -6,780 -9.69 17,347 19.66 2.6370
2018-08-13 2018-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 69,976 -5,368 -7.12 14,497 16.50 2.4632
2018-05-08 2018-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 75,344 -750 -0.99 12,444 19.42 2.0494
2018-02-12 2017-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 76,094 4,681 6.55 10,420 7.17 1.7686
2017-11-13 2017-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 71,413 3,744 5.53 9,723 18.36 1.7011
2017-08-03 2017-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 67,669 1,146 1.72 8,215 16.67 1.5628
2017-05-12 2017-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 66,523 7,615 12.93 7,041 17.62 1.3771
2017-02-13 2016-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 58,908 4,680 8.63 5,986 8.15 1.2794
2016-11-08 2016-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 54,228 -3,624 -6.26 5,535 -19.78 1.1956
2016-08-10 2016-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 57,852 -3,665 -5.96 6,900 4.74 1.5040
2016-05-12 2016-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 61,517 -1,032 -1.65 6,588 -2.86 1.4527
2016-02-16 2015-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 62,549 -555 -0.88 6,782 25.48 1.5326
2015-11-16 2015-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 63,104 4,000 6.77 5,405 -9.37 1.3470
2015-08-14 2015-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 59,104 32,994 126.37 5,964 196.27 1.3743
2015-05-15 2015-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 26,110 180 0.69 2,013 45.87 0.5244
2015-02-17 2014-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 25,930 4,535 21.20 1,380 37.31 0.3646
2014-11-14 2014-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 21,395 2,170 11.29 1,005 -16.11 0.2786
2014-08-14 2014-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 19,225 -1,775 -8.45 1,198 -15.22 0.3228
2014-05-15 2014-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 21,000 -1,360 -6.08 1,413 20.15 0.4049
2014-02-11 2013-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 22,360 0 0.00 1,176 21.49 0.3449
2013-11-14 2013-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 22,360 -3,255 -12.71 968 1.04 0.2953
2013-08-14 2013-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 25,615 25,615 958 0.3141
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.